117 results about "Carbohydrate tolerance" patented technology

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention discloses a composite double-protein hypoglycemic peptide as well as a preparation method and application thereof, and belongs to the technical field of animal and plant source double-protein active peptides. The method comprises the following steps: performing computer simulation enzyme digestion and virtual screening by utilizing bioinformatics to determine a protein raw material and protease, performing enzymolysis on animal and plant double proteins (soybean protein and casein) serving as raw materials by adopting neutral protease, and performing separation, purification and structural identification, thereby obtaining the protein. The protein peptide fragment with high alpha-glucosidase inhibitory activity is obtained by virtually screening molecular docking, and the amino acid sequences of the protein peptide fragment are shown as SEQ ID No: 6, SEQ ID No: 9 and SEQ ID No: 24. The compound double-protein peptide sequence provided by the invention has an inhibiting effect on the activity of alpha-glucosidase, can be used for preventing and treating diabetes mellitus, and can be used for long-term health care or treatment of people with impaired glucose tolerance or diabetics as a functional food ingredient.

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating polycystic ovarian syndrome (PCOS). The beta-elemonic acid is screened from a medicinal and edible library, and experiments prove that the beta-elemonic acid can remarkably improve the PCOS ovarian form and the number of mature follicles, normalize the disordered estrus cycle, remarkably improve the serum hormone level and further remarkably improve the sugar tolerance, insulin tolerance and weight of PCOS. The beta-elemonic acid disclosed by the invention is a compound based on homology of medicine and food, can be used as a medicine as well as a natural ingredient of food, is relatively low in toxicity, ensures the safety after long-term use, is relatively low in safety evaluation cost of a relatively brand-new synthetic compound, and can be applied to development and preparation of a medicine or a lead compound thereof for preventing and / or treating PCOS, or a health care product.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The invention provides a rhizoma polygonati extract as well as a preparation method and application thereof in prevention and control of glucose and lipid metabolism disorder. According to the invention, an effective component group consisting of effective parts of flavonoids and saponins is extracted from a traditional Chinese medicinal material polygonatum sibiricum, the sum of the actual contents accounts for more than 50% of the total weight of the polygonatum sibiricum extract, and meanwhile, the effective component group is used for preparing medicines for preventing and / or treating impaired glucose tolerance and glucose and lipid metabolism disorder. The traditional Chinese medicine composition is clear in curative effect, controllable in quality and easy to industrialize in preparation process, various proper dosage forms can be prepared according to clinical requirements, and a convenient, effective, stable and controllable modern traditional Chinese medicine is provided for clinical application.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

Provided is a use of Staphylococcus lentus with an accession number of GDMCC 1.247 in preparation of a composition for preventing and treating insulin resistance or type 2 diabetes. This strain can significantly reduce the weight gain induced by a high-fat diet (HFD), improve the glucose tolerance, promote the insulin secretion, improve the insulin resistance, and significantly improve the immunity and inflammation.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The invention discloses a probiotic agent for relieving prediabetic action and application thereof, and belongs to the technical field of microorganisms. Experiments prove that bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics can relieve the prediabetic stage, which is specifically embodied in reducing weight gain of mice in the prediabetic stage, regulating blood sugar metabolism, improving sugar tolerance and insulin resistance, protecting liver and pancreas tissues, being beneficial to increasing the diversity of intestinal flora, recovering the structure of the intestinal flora, and improving the immunity of the mice in the prediabetic stage. The invention also provides a preparation method of the bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. The bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. And the growth of beneficial bacteria related to metabolic disorder is enriched and regulated. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The application discloses a composition containing burdock polysaccharide for reducing blood sugar of type 2 diabetes patients and a preparation method and application thereof, and belongs to the technical field of medicine and food. The composition contains burdock polysaccharide, chitooligosaccharide, chlorogenic acid, epicatechin, resveratrol, ginsenoside Rd, and vitamin D, vitamin B1, vitamin B6, vitamin B12, magnesium glycinate and thaumatin protein. The application takes burdock polysaccharide as a core long-acting component, takes chitooligosaccharide as a short-acting synergistic component, constructs a long-short-acting synergistic blood sugar reducing system, and realizes the organic combination of rapid blood sugar reduction and stable blood sugar control. Experiments show that the composition can significantly reduce the fasting blood sugar of type 2 diabetes model rats, improve insulin resistance and glucose tolerance, reduce blood lipid and inflammatory factor levels, and reduce oxidative stress damage. The alpha-glucosidase inhibitory activity and in-vivo comprehensive blood sugar reducing effect of the composition are better than those of single burdock polysaccharide, and the composition has good taste and is suitable for long-term use of diabetes patients.

The utility model belongs to the technical field of detection of diabetic patients in hospitals, and particularly relates to a glucose oral liquid instant heating cup suitable for a glucose tolerance test, which comprises a cup body, a cup cover arranged at the top of the cup body, a bottom box arranged at the bottom of the cup body, a bottom cover arranged at the bottom of the bottom box, and an inner container, an exhaust hole, a bottom groove, a limiting groove, a leak hole and an interlayer, an inner container is arranged in the cup body, an exhaust hole is formed in the outer side of the cup body, a bottom groove is formed in the bottom of the cup body, a limiting groove is formed in the bottom groove, a leakage hole is formed in the bottom of the inner container, an interlayer is formed between the inner container and the cup body, and the bottom box comprises an air outlet, a sealing ball and a jacking spring. Through the leakage hole, the bottom box, the air outlet, the sealing ball, the jacking spring and the bottom cover, the temperature of a patient during drinking is easily controlled, it is guaranteed that a sugar tolerance test cannot be conducted continuously, through the bottom groove, the limiting groove, the bottom box, the sealing ball, the jacking spring and the bottom cover, operation is convenient and fast, and the workload of nursing staff is reduced.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses a mesenchymal stem cell preparation expressing FOXO3 and FGF21 and application thereof, relates to biological medicine, and a parent plasmid carrying a therapeutic gene of the mesenchymal stem cell expressing FOXO3 and FGF21 has a nucleotide sequence as shown in SEQ ID No: 01; the application provides a mesenchymal stem cell preparation capable of simultaneously expressing FOXO3 and FGF21, which can effectively improve insulin glucose tolerance, effectively reduce the content of glycosylated hemoglobin, and has the potential to treat human type 2 diabetes.

The invention provides a traditional Chinese medicine composition for diabetes and application, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine composition is composed of twelve traditional Chinese medicines of prepared rehmannia root, pulp of dogwood fruit, Chinese yam, rhizoma alismatis, poria cocos, cortex moutan, wolfberry fruit, semen cuscutae, rhizoma polygonati, radix polygonati officinalis, radices trichosanthis and mantis egg-case. Animal experiments show that the traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving the weight loss trend of diabetic mice and improving the glucose metabolism disorder state by reducing fasting blood-glucose and 2h glucose tolerance; in addition, the traditional Chinese medicine composition can increase TP and GLB contents in serum of mice, reduce ALT and AST activity, effectively repair anabolism functions of livers of diabetic mice and inhibit inflammation and necrosis of hepatocytes, and a safe and efficient treatment scheme is provided for diabetes.

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention relates to a synbiotic composition comprising probiotics and dietary fiber, wherein the probiotics are selected from Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) BPB22; dietary fiber is derived from one or more of white lentils, goji berries, red dates, bitter melon, lotus seeds, buckwheat, Chinese yam, oats, corn silk, and coix seed. The synbiotic composition of the present invention can significantly improve symptoms of a high-fat diet, including excessive caloric intake, weight gain, fat accumulation, muscle loss, impaired insulin sensitivity, impaired glucose tolerance, insulin resistance, and decreased fecal short-chain fatty acid levels.

The invention relates to a low glycemic index composition which comprises the following components in percentage by weight: 10-35% of a protein composition, 20-55% of a fat composition, 5-35% of a saccharide composition, 1-15% of a dietary fiber composition, 1-2% of a trace element composition, 0.1-1.5% of a vitamin composition and 5-20% of a macroelement composition, according to the composition with the low glycemic index, all the components are scientifically compounded, the digestion and absorption speed of carbohydrates is effectively controlled, the blood glucose level of diabetic patients or patients with impaired glucose tolerance is effectively controlled, comprehensive and balanced nutrition is provided for the diabetic patients or the patients with impaired glucose tolerance, and the composition is beneficial for repairing and improving the immunity of the diabetic patients or the patients with impaired glucose tolerance; and the feed also has the advantages of excellent quality uniformity, stability and fluidity, light taste, suitability for tube feeding and the like.

The invention discloses an application of a tripeptide in preparation of a medicine for treating non-alcoholic fatty liver disease. The tripeptide is phenylalanine-proline-isoleucine (FPI). The treatment effect of the FPI on the non-alcoholic fatty liver is determined by adopting a classical non-alcoholic fatty liver mouse model. Technicians in the field know important characteristics of glucose and lipid metabolism disorder, insulin resistance, liver lipid accumulation and liver injury in non-alcoholic fatty liver. Experimental data show that the FPI can significantly reduce the weight of a mouse with the non-alcoholic fatty liver disease, significantly improve glucose tolerance and insulin tolerance of the mouse, improve liver injury, significantly reduce liver lipid accumulation of the mouse, and significantly reduce the levels of TG, ALT and AST in serum of the mouse. Therefore, the FPI has the prospect of being developed into the medicine for treating the non-alcoholic fatty liver disease.

The invention discloses an application of miR-100 sponge in preparation of a medicine for treating type 2 diabetes mellitus. The miR-100 sponge can inhibit miR-100 in a targeted manner and close the expression of miR-100 in beta cells. The nucleic acid construct is further prepared from the nucleic acid construct, AAV8-mmu-miR-100 Sponge (AAV-Sponge) is injected into pancreatic ducts of obese diabetes mellitus mice, after treatment is conducted for 4 weeks, it is found that the sugar tolerance of the mice in a treatment group is improved, the GSIS function of beta cells is improved, and the nucleic acid construct is expected to be further applied to preparation of the medicine for treating the type 2 diabetes mellitus. The problems that current treatment methods for type 2 diabetes mellitus are deficient and the treatment cost is high are solved.

The present application discloses a two-arm branched fatty acid side chain, a receptor agonist modified therewith, and a use thereof. By adjusting the number and structure of side chain arms of the fatty acid chain, optimizing the type of a core molecule, and using the fatty acid chain to modify a receptor agonist, the present application significantly improves the physical and chemical stability of the receptor agonist and the therapeutic effect of the receptor agonist on reducing blood glucose and body weight. The fatty acid chain and the receptor agonist modified therewith disclosed in the present application can reduce blood glucose levels and improve sugar tolerance and has the effects of controlling appetite, food intake, and caloric intake, increasing energy consumption, preventing weight gain, promoting weight loss, and reducing excess body weight. In addition, the fatty acid chain and the receptor agonist modified therewith disclosed in the present application have relatively long half-life and can effectively prolong in vivo drug actions.

The present invention relates to the field of pharmaceutical combination components and discloses a GLP-1 / Gcg dual agonist compound. The GLP-1 / Gcg dual agonist compound described above is used for manufacturing a pharmaceutical composition for treating diseases. The pharmaceutical composition is used for manufacturing a medicament for treating at least one of diseases including type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or indigestion or gastric ulcer, liver fibrosis and pulmonary fibrosis.